Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

• ClinicalTrials.gov Identifier: NCT04768881
• Recruitment Status: Active, not recruiting
• First Posted: February 24, 2021
• Last Update Posted: February 1, 2023
• Sponsor: Karyopharm Therapeutics Inc
• Information provided by (Responsible Party): Karyopharm Therapeutics Inc

Study Description

Brief Summary:

Approximately 40 participants with locally advanced or metastatic melanoma will be enrolled in 20 sites in the United States into 1 of the following 2 arms: Primary resistance to initial checkpoint inhibitor (CPI) therapy in Arm A and Acquired resistance to initial CPI therapy in Arm B. Participants who have disease progression (PD) after discontinuation of CPIs, especially in neoadjuvant or adjuvant therapy, will be considered to have acquired resistance in this study. Participants will receive study treatment (Selinexor and Pembrolizumab) until PD, intolerable toxicity or withdrawal from the study, whichever occurs first.

Condition or disease	Intervention/treatment	Phase
Locally Advanced Unresectable or Metastatic Melanoma	Drug: Selinexor; Drug: Pembrolizumab	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 40 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
• Actual Study Start Date: May 12, 2021
• Estimated Primary Completion Date: February 2023
• Estimated Study Completion Date: November 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: Arm A: Primary resistance to Initial CPI Therapy; Participants will receive a dose of 80 milligrams (mg) selinexor orally once weekly (QW) and a dose of pembrolizumab 400 mg intravenously (IV) once in every six weeks (Q6W), both on Day 1 of a 6-week cycle until progressive disease (PD), intolerable toxicity or withdrawal from the study, whichever occurs first.	Drug: Selinexor; Dose and formulation: 80 mg (4 tablets of 20 mg); Other Names: KPT-330; XPOVIO™; Drug: Pembrolizumab; Dose and formulation: 400 mg (25 milligrams per milliliter [mg/mL]) Solution; Other Name: Keytruda™
Experimental: Arm B: Acquired Resistance to Initial CPI Therapy; Participants will receive a dose of 80 mg selinexor orally once weekly (QW) and a dose of pembrolizumab 400 mg IV Q6W, both on Day 1 of a 6-week cycle until PD, intolerable toxicity or withdrawal from the study, whichever occurs first.	Drug: Selinexor; Dose and formulation: 80 mg (4 tablets of 20 mg); Other Names: KPT-330; XPOVIO™; Drug: Pembrolizumab; Dose and formulation: 400 mg (25 milligrams per milliliter [mg/mL]) Solution; Other Name: Keytruda™

Outcome Measures

Primary Outcome Measures :

1. Overall Response Rate (ORR) [ Time Frame: Up to 24 months ]

Secondary Outcome Measures :

1. Progression-free Survival (PFS) [ Time Frame: Up to 24 months ]
2. Overall Survival (OS) [ Time Frame: Up to 24 months ]
3. Complete Response Rate (CRR) [ Time Frame: Up to 24 months ]
4. Duration of Response (DOR) [ Time Frame: Up to 24 months ]
5. Disease Control Rate (DCR) [ Time Frame: Up to 24 months ]
6. Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs [ Time Frame: Baseline up to 30 Days after End of Treatment (EoT) (EoT: Less than or equal to [≤28] days post-treatment discontinuation) ]
7. Number of Participants with Clinically Significant Safety Observations: Clinical Laboratory (Hematology and Chemistry), Vital Signs and Physical Examination [ Time Frame: Baseline up to 30 Days after EoT (EoT: ≤28 days post-treatment discontinuation) ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Age greater than or equal to (≥) 18 years at the time of informed consent.

• Participant must have a histologically confirmed diagnosis of locally advanced unresectable stage III or metastatic stage IV melanoma not amenable to local therapy.

  1. Participants must have confirmed PD per Response Evaluation Criteria in Solid Tumors (RECIST) on or within 12 weeks of the last dose of anti-PD-1/L1 monotherapy or combination therapy (including relatlimab or other anti-LAG-3 mAb) per Society for Immunotherapy in Cancer Guidelines (Kluger,2020).
  2. Arm A (primary resistance): participant has disease progression after receiving at least 6 weeks of prior anti-PD-1/L1 mAb with the best response as PD, or stable disease (SD) less than (<) 6 month (participants with a partial response [PR] or complete response [CR] who have disease progression within 6 months will be considered to have primary resistance in this study).
  3. Arm B (secondary/acquired resistance): participant has disease progression after receiving at least 6 months of prior anti-PD-1/L1 mAb with the best response as CR, PR, or SD greater than (>) 6 months (participants who have disease progression after neoadjuvant or adjuvant therapy, will be considered to have secondary resistance in this study).
  4. Participants who progress on or within 12 weeks after elective discontinuation of anti-PD-1/L1 mono or combination treatment in the absence of PD or treatment limiting toxicity must have confirmed PD per RECIST.
• Participants should have at least 1 prior line of CPI therapy but no more than 2.
• Measurable disease according to RECIST v1.1.
• Participants with stable previously treated brain metastases are permitted in this study.
• Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (≤) 1.

• Adequate bone marrow function at screening, defined as:

  1. Absolute neutrophil count (ANC) ≥1.5 * 10^9 per liter (L).
  2. Hemoglobin ≥10 gram per deciliter (gm/dL) (≥6.2 millimoles per liter [mmol/L]).
  3. Platelet count ≥100 * 10^9/L.
• Serum direct bilirubin ≤1.5 * upper limit of normal (ULN); aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 * ULN (with confirmed liver metastases: AST and ALT ≤5 * ULN).
• Calculated creatinine clearance (CrCl) ≥15 milliliters per minute (mL/min) based on the Cockcroft and Gault formula.
• Female participants of childbearing potential must have a negative serum pregnancy test at screening and agree to use highly effective methods of contraception throughout the study and for at least four months following the last dose of study treatment. Childbearing potential excludes: Age >50 years and naturally amenorrhoeic for >1 year, or previous bilateral salpingo-oophorectomy, or hysterectomy.
• Male participants who are sexually active must use highly effective methods of contraception throughout the study and for at least four months following the last dose of study treatment. Male participants must agree not to donate sperm during the study treatment period.
• Written informed consent signed in accordance with federal, local, and institutional guidelines.

Exclusion Criteria:

• Metastatic uveal or ocular melanoma.
• Active central nervous system (CNS) metastases or other CNS (e.g., meningeal) involvement.

• Participants must have resolution or improvement of immune-mediated treatment related adverse reactions related to prior treatment(s) to Grade ≤1 without steroid maintenance therapy or his or her previous baseline prior to the corresponding CPI therapy

  a. History of immune-mediated treatment related adverse reactions leading to discontinuation of prior anti-programmed death protein 1 (PD-1), anti-programmed death protein ligand 1 (PD-L1), or anti programmed death protein ligand 2 (PD-L2) monoclonal antibodies (mAbs) or severe hypersensitivity reaction to any mAb or any excipients which in the opinion of the Investigator precludes future use of anti-PD-1/PDL1 therapy.

• Concurrent systemic steroid therapy higher than physiologic dose (>10 milligrams per day [mg/day] of prednisone or equivalent).
• Previous treatment with selinexor or other exportin 1 (XPO1) inhibitors.

• Insufficient time since or not recovered from procedures or anti-cancer therapy, defined as:

  1. Not recovered from major surgery ≤28 days prior to Day 1 dosing. Minor procedures, such as biopsies, dental work, or placement of a port or intravenous (IV) line for infusion are permitted.
  2. Have ongoing clinically significant anti-cancer therapy-related toxicities Common Terminology Criteria for Adverse Events (CTCAE) Grade >1. In specific cases, participants whose toxicity has stabilized or with Grade 2 non-hematologic toxicities can be allowed following documented approval by the Sponsor's Medical Monitor
  3. Had last dose of previous anti-cancer therapy ≤14 days prior to Day 1 dosing
  4. Palliative radiotherapy >14 days prior to the study is allowed
  5. Received investigational drugs in other clinical trials within 28 days, or 5 half-lives of the investigational drug (whichever is shorter), prior to Cycle 1 Day 1 (C1D1).
• Live-attenuated vaccine (e.g., nasal spray influenza vaccine) ≤14 days prior to the intended C1D1.
• Impairment of gastrointestinal (GI) function or GI disease that could significantly alter the absorption of selinexor (e.g., vomiting, or diarrhea that is CTCAE version 5.0 grade >1).
• Life expectancy less than (<) 4 months based on the opinion of the Investigator
• Active pneumonitis requiring steroid therapy.
• Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics, antivirals, or antifungals within 7 days prior to first dose of study treatment; however, prophylactic use of these agents is acceptable (including parenteral).
• Any life-threatening illness, medical condition, or organ system dysfunction which, in the Investigator's opinion, could compromise the participant's safety, prevent the participant from giving informed consent, or being compliant with the study procedures.
• Female participants who are pregnant or lactating.
• Active hepatitis B virus treated with antiviral therapy for hepatitis B within 8 weeks with a viral load >100 international units per milliliter (IU/mL).
• Untreated hepatitis C virus positive without documentation of negative viral load per institutional standard.
• Human immunodeficiency virus positive with CD4+T-cells ≤350 cells per microliter, positive viral load per institutional standard, and a history of acquired immunodeficiency syndrome defining opportunist infections in the last year.

Contacts and Locations

Locations

United States, California

UCLA

Los Angeles, California, United States, 90095

TOI Clinical Research

Pasadena, California, United States, 91105

United States, Florida

BRCR Global

Plantation, Florida, United States, 33322

United States, Minnesota

Minnesota Oncology Hematology

Minneapolis, Minnesota, United States, 55404

United States, Nebraska

Great Plains Health

North Platte, Nebraska, United States, 69101

United States, New Jersey

John Theurer Cancer Center at Hackensack University Medical Center

Hackensack, New Jersey, United States, 07601

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, United States, 08901

United States, New York

New York Oncology Hematology

Albany, New York, United States, 12206

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065

United States, Ohio

OH Care Clinical Trials

Cincinnati, Ohio, United States, 45242

Cleveland Clinic Foundation

Cleveland, Ohio, United States, 44144

United States, Texas

Texas Oncology-Austin Central

Austin, Texas, United States, 78731

Texas Oncology - Baylor Sammons Center

Dallas, Texas, United States, 75246

Sponsors and Collaborators

Karyopharm Therapeutics Inc

More Information

• Responsible Party: Karyopharm Therapeutics Inc
• ClinicalTrials.gov Identifier: NCT04768881
• Other Study ID Numbers: XPORT-MEL-033
• First Posted: February 24, 2021
• Last Update Posted: February 1, 2023
• Last Verified: January 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Karyopharm Therapeutics Inc:

Karyopharm; Locally advanced unresectable or metastatic melanoma; KPT-330; Recurrent advanced melanoma; Selinexor; Pembrolizumab

Additional relevant MeSH terms:

Melanoma; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Pembrolizumab; Antineoplastic Agents, Immunological; Antineoplastic Agents